CYLD and skin neoplasm: We have successfully validated the method according to the EMA guidance on bioanalytical method validation [12] and demonstrated its applicability to determine the drug's tumor distribution in skin tumor punch biopsies obtained from patients with CYLD mutations participating in the current clinical trial.